Research Publications

Dr. Theodore Lampidis continues to be a global leader in 2-DG research. See the following summary of key research publications found in the National Center for Biotechnology Information (NCBI) website as well as other respected medical journals.

Combining 2-Deoxy-D-glucose with fenofibrate leads to tumor cell death mediated by simultaneous induction of energy and ER stress. Huaping Liu, Metin Kurtoglu, Clara Lucia León-Annicchiarico, Cristina Munoz-Pinedo, Julio Barredo, Guy Leclerc, Jaime Merchan, Xiongfei Liu, Theodore J. Lampidis. 2016 May 10. [Epub ahead of print]. View Article

Targeting cisplatin-resistant human tumor cells with metabolic inhibitors. Sullivan EJ, Kurtoglu M, Brenneman R, Liu H, Lampidis TJ. Cancer Chemother Pharmacol. 2013 Dec 19. [Epub ahead of print]. View Article

Increased sensitivity to glucose starvation correlates with downregulation of glycogen phosphorylase isoform PYGB in tumor cell lines resistant to 2-deoxy-D-glucose. Philips KB, Kurtoglu M, Leung HJ, Liu H, Gao N, Lehrman MA, Murray TG, Lampidis TJ. Cancer Chemother Pharmacol. 2013 Dec 1. [Epub ahead of print]. View Article

Conversion of 2-deoxyglucose-induced growth inhibition to cell death in normoxic tumor cells. Liu H, Kurtoglu M, Cao Y, Xi H, Kumar R, Axten JM, Lampidis TJ. Cancer Chemother Pharmacol. 2013 Jul;72(1):251-62. doi: 10.1007/s00280-013-2193-y. Epub 2013 May 23. View Article

Endoplasmic reticulum stress induced by 2-deoxyglucose but not glucose starvation activates AMPK through CaMKKβ leading to autophagy. Xi H, Barredo JC, Merchan JR, Lampidis TJ. Biochem Pharmacol. 2013 May 15;85 (10):1463-77. doi: 10.1016/j.bcp.2013.02.037. Epub 2013 Mar 13.

Models and discovery strategies for new therapies of retinoblastoma. Houston SK, Lampidis TJ, Murray TG. Expert Opin Drug Discov. 2013 Apr; 8(4):383-94. doi: 10.1517/17460441.2013.772975. Epub 2013 Feb 22. Review. View Article

A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, Dipaola RS, Stein MN, Rocha Lima CM, Schlesselman JJ, Tolba K, Langmuir VK, Kroll S, Jung DT, Kurtoglu M, Rosenblatt J, Lampidis TJ. Cancer Chemother Pharmacol. 2012 Dec 11.  View Article

Activation of the unfolded protein response by 2-deoxy-D-glucose inhibits kaposi's sarcoma-associated herpesvirus replication and gene expression. Leung HJ, Duran EM, Kurtoglu M, Andreansky S, Lampidis TJ, Mesri EA. Antimicrob Agents Chemother. 2012 Nov;56(11):5794-803. doi: 10.1128/AAC.01126-12. Epub 2012 Aug 27. View Article

Retinoblastoma treatment: impact of the glycolytic inhibitor 2-deoxy-d-glucose on molecular genomics expression in LH(BETA)T(AG) retinal tumors. Piña Y, Houston SK, Murray TG, Koru-Sengul T, Decatur C, Scott WK, Nathanson L, Clarke J, Lampidis TJ. Clin Ophthalmol. 2012;6:817-30. doi: 10.2147/OPTH.S29688. Epub 2012 May 29. View Article

Inhibition of Akt potentiates 2-DG-induced apoptosis via downregulation of UPR in acute lymphoblastic leukemia. DeSalvo J, Kuznetsov JN, Du J, Leclerc GM, Leclerc GJ, Lampidis TJ, Barredo JC. Mol Cancer Res. 2012 Jul; 10(7):969-78. doi: 10.1158/1541-7786.MCR-12-0125. Epub 2012 Jun 12. View Article

Retinoblastoma treatment: utilization of the glycolytic inhibitor, 2-deoxy-2-fluoro-D-glucose (2-FG), to target the chemoresistant hypoxic regions in LH(BETA)T(AG) retinal tumors. Piña Y, Decatur C, Murray TG, Houston SK, Lopez-Cavalcante M, Hernandez E, Celdran M, Shah N, Feuer W, Lampidis TJ. Invest Ophthalmol Vis Sci. 2012 Feb 27;53(2):996-1002. doi: 10.1167/iovs.11-8265. Print 2012 Feb. View Article

The relationship of thioredoxin-1 and cisplatin resistance: its impact on ROS and oxidative metabolism in lung cancer cells. Wangpaichitr M, Sullivan EJ, Theodoropoulos G, Wu C, You M, Feun LG, Lampidis TJ, Kuo MT, Savaraj N. Mol Cancer Ther. 2012 Mar;11(3):604-15. doi: 10.1158/1535-7163.MCT-11-0599. Epub 2012 Jan 16. View Article

Advanced retinoblastoma treatment: targeting hypoxia by inhibition of the mammalian target of rapamycin (mTOR) in LH(BETA)T(AG) retinal tumors. Piña Y, Decatur C, Murray T, Houston S, Gologorsky D, Cavalcante M, Cavalcante L, Hernandez E, Celdran M, Feuer W, Lampidis TJ. Clin Ophthalmol. 2011;5:337-43. doi: 10.2147/OPTH.S16172. Epub 2011 Mar 7.

Novel retinoblastoma treatment avoids chemotherapy: the effect of optimally timed combination therapy with angiogenic and glycolytic inhibitors on LH(BETA)T(AG) retinoblastoma tumors. Houston SK, Piña Y, Murray TG, Boutrid H, Cebulla C, Schefler AC, Shi W, Celdran M, Feuer W, Merchan J, Lampidis TJ. Clin Ophthalmol. 2011 Jan 27;5:129-37. doi: 10.2147/OPTH.S15179.

Antiangiogenic activity of 2-deoxy-D-glucose. Merchan JR, Kovács K, Railsback JW, Kurtoglu M, Jing Y, Piña Y, Gao N, Murray TG, Lehrman MA, Lampidis TJ. PLoS One. 2010 Oct 27; 5(10):e13699. doi: 10.1371/journal.pone.0013699. View Article

Focal, periocular delivery of 2-deoxy-D-glucose as adjuvant to chemotherapy for treatment of advanced retinoblastoma. Pina, Y, Houston, SK, Murray, TG, Boutrid, H, Celdran, M. Feuer, W, Shi, W, Hernandez, E, Lampidis, TJ. Invest Ophthalmol Vis Sci. Dec;51(12):6149-56, 2010.

2-Deoxy-D-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion. Xi, H, Kurtoglu, M, Liu, H, Wangpaichitr, M, You, M, Liu, X, Savaraj, N, Lampidis, TJ. Cancer Chemother Pharmacol. Apr;67(4):899-910, 2011.

High endoplasmic reticulum activity renders multiple myeloma cells hypersensitive to mitochondrial inhibitors. Kurtoglu, M, Philips, K, Liu, H, Boise, LH, Lampidis, TJ. Cancer Chemother Pharmacol. May;66(1):129-40, 2010.

From delocalized lipophilic cations to hypoxia: blocking tumor cell mitochondrial function leads to therapeutic gain with glycolytic inhibitors. Kurtoglu, M, Lampidis, TJ. Mol Nutr Food Res. Jan;53(1):68-75, 2009.

Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-D-glucose under hypoxia in lung cancer cell lines. Wangpaichitr, M, Savaraj, N, Maher, J, Kurtoglu, M, Lampidis, TJ. Mol Cancer Ther. Jun;7(6):1506-13, 2008.

Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins. Wangpaichitr, M, Wu, C, You, M, Kuo, MT, Feun, L, Lampidis, TJ, Savaraj, N. Eur J Pharmacol. Jun 12, 2008.

Targeting hypoxia, a novel treatment for advanced retinoblastoma. Boutrid, H, Jockovich, ME, Murray, T, Pina, Y, Feuer, WJ, Lampidis, TJ, Cebulla, C. Invest Ophthalmol Vis Sci. Jul;49(7):2799-805, 2008.

Differential Expression of Glut 1 mRNA and Protein Levels Correlates with Increased Sensitivity to the Glyco-Conjugated Nitric Oxide Donor (2-glu-SNAP) in Different Tumor Cell Types. Subbarayan, PR, Wang, PG, Lampidis, TJ, Ardalan, B, Braunschweiger, P. Chemother. Feb 20(1):106-11, 2008.

Differential toxic mechanisms of 2-deoxy-D-glucose versus 2-fluorodeoxy-D-glucose in hypoxic and normoxic tumor cells. Kurtoglu M, Maher JC, Lampidis TJ. Antioxid Redox Signal. Review, Sep (9):1383-90, 2007.

Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Kurtoglu M, Gao N, Shang J, Maher JC, Lehrman MA, Wangpaichitr M, Savaraj N, Lane AN, Lampidis TJ. Mol Cancer Ther. (11):3049-58, 2007.

Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor, 2-deoxy-D-glucose. Maher, JC, Wangpaichitr, MC, Savaraj, N, Kurtoglu, M, Lampidis, TJ. Mol Cancer Ther., Feb (2):732-41, 2007.

Relative Efficacy of 2-halogen substituted D-glucose analogs in blocking glycolysis and killing "hypoxic tumor cells". Lampidis, TJ , Kurtoglu, M, Maher, J, Liu, HP, Krishan, A, Sheft, V, Szymanski, S, Fokt, I, Rudnicki, WR, Ginalski, K, Lesyng, B and Priebe W. Cancer Chemother Pharmacol., Dec;58(6):725-34, 2006. [Epub ahead of print].

Pro-collagen alpha 1 type I: A Potential Aide in Histopathological Grading of Glioma. Savaraj N, Wu C, Landy H, Wangpaijit M, Wei M, Kuo T, Robles C, Furst AJ, Lampidis TJ & Feun L. Cancer Invest. 2005; 23(7):577-81.

Overcoming Cisplatin Resistance by mTOR Inhibitor in Lung Cancer. Wu C, Wangpaichitr M, Feun L, Kuo MT, Robles C, Lampidis TJ , and Savaraj N. Molecular Cancer, 4:25 doi:10.1186/1476-4598, 2005.

Differential sensitivity to 2-deoxy-D-glucose between two pancreatic cell lines correlates with GLUT-1 expression. Maher JC, Savaraj N, Priebe W, Liu H, Lampidis TJ. Pancreas, 2005, (2): e34-9.

2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF, De Young LR, Lampidis TJ. Cancer Res. 2004,64(1):31-4.

Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemother Pharmacol. Maher JC, Krishan A, Lampidis TJ. 2004, 53(2):116-22.Epub 2003 Nov 7.

Overexpression of mutated MRP4 in cisplatin resistant small cell lung cancer cell line: collateral sensitivity to azidothymidine. Savaraj N, Wu C, Wangpaichitr M, Kuo MT, Lampidis TJ, Robles C, Furst AJ, Feun L. Int J Oncol. 2003, (1):173-9.

Multidrug resistance correlates with overexpression of Muc4 but inversely with P-glycoprotein and multidrug resistance related protein in transfected human melanoma cells. Hu YP, Haq B, Carraway KL, Savaraj N, Lampidis TJ. Biochem Pharmacol. 2003, 65(9):1419-25.

Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C). Liu H, Savaraj N, Priebe W, Lampidis TJ. Biochem Pharmacol. 2002 Dec 15;64(12):1745-51.

Hypersensitization of Tumor Cells to Glycolytic Inhibitors. Liu, H. Hu, Savaraj, N. Priebe, W, and Lampidis, TJ. Biochemistry, 40:5542-5547, 2001.

r0 Tumor Cells: A model for studying whether mitochondria are targets for Rhodamine 123, Doxorubicin and other drugs. Hu, YP, Moraes, C, Savaraj, N, Priebe, W, and Lampidis TJ. Biochem. Pharm. 60:1897-1905, 2000.


View published research articles by Dr. Lampidis in the National Library of Medicine